Revital Kariv from Bellevue, WA, age 50

view source

Antibodies To Angiogenesis Inhibiting Domains Of Cd148
view source
US Patent:

20050287140, Dec 29, 2005
Filed:

Apr 21, 2005
Appl. No.:

11/112240
Inventors:

James Smothers - Lake Forest Park WA, US
William Fanslow - Normandy Park WA, US
Revital Kariv - Bellevue WA, US
Assignee:

Amgen Inc. - Seattle WA
International Classification:

A61K039/395
C07K016/30
US Classification:

424144100, 530388220
Abstract:

The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD 148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided.

Antibodies Of Angiogenesis Inhibiting Domains Cd148
view source
US Patent:

20060002931, Jan 5, 2006
Filed:

Apr 22, 2005
Appl. No.:

11/112304
Inventors:

William Fanslow - Normandy Park WA, US
Revital Kariv - Bellevue WA, US
James Smothers - Lake Forest Park WA, US
Assignee:

Amgen Inc. - Seattle WA
International Classification:

G01N 33/53
G01N 33/567
A01K 67/027
C07H 21/04
A61K 39/395
C12P 21/06
US Classification:

424144100, 435007200, 435069100, 435320100, 435334000, 530388220, 536023530, 800018000
Abstract:

Anti-CD148 antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind CD148 epitopes and activate CD148 function, such as inhibition of angiogenesis. Epitopes that can be used to activate CD148 function and anti-angiogenesis activity are also described, as well as methods of identifying compounds that can bind them.

Antibodies To Angiogenesis Inhibiting Domains Of Cd148
view source
US Patent:

20090263383, Oct 22, 2009
Filed:

Feb 27, 2008
Appl. No.:

12/072737
Inventors:

James F. Smothers - Quincy MA, US
Revital Kariv - Bellevue WA, US
Assignee:

Amgen Inc. - Seattle WA
International Classification:

A61K 39/395
C07K 16/28
C12N 15/13
C12N 15/85
C12N 5/16
C12P 21/02
C12N 5/00
A61P 35/00
US Classification:

4241331, 5303879, 5303873, 4241391, 536 2353, 4353201, 435328, 435 696, 435377, 435331
Abstract:

The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD 148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided.

Revital Kariv